202 related articles for article (PubMed ID: 37042120)
1. Clinical features and risk factors of lung cancer in elderly patients with dermatomyositis.
Zhou B; Li S; Xie X; Xu S; Li F; Long L
Thorac Cancer; 2023 May; 14(13):1171-1178. PubMed ID: 37042120
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
Yang H; Yan T; Zhang X; Sun W; Liu L; Du Y; Xue J
Clin Rheumatol; 2022 Aug; 41(8):2439-2448. PubMed ID: 35422109
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
6. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients.
Ikeda N; Takahashi K; Yamaguchi Y; Inasaka M; Kuwana M; Ikezawa Z
J Dermatol; 2011 Oct; 38(10):973-9. PubMed ID: 21883412
[TBL] [Abstract][Full Text] [Related]
7. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
8. [Risk Factors of Respiratory Failure in the Dermatomyositis Patients with Interstitial Lung Disease].
Zhang SH; Peng Y; Xie QB; Yin G; Yan B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Mar; 49(2):188-194. PubMed ID: 29737058
[TBL] [Abstract][Full Text] [Related]
9. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
10. [Risk factors analysis and prediction model establishment of malignant tumor in patients with polymyositis/dermatomyositis].
Wang YF; Li HX; Feng Y; Zhang Y; Wu ZB
Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(25):1903-1910. PubMed ID: 37402671
[No Abstract] [Full Text] [Related]
11. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis.
Matsushita T; Hasegawa M; Fujimoto M; Hamaguchi Y; Komura K; Hirano T; Horikawa M; Kondo M; Orito H; Kaji K; Saito Y; Matsushita Y; Kawara S; Yasui M; Seishima M; Ozaki S; Kuwana M; Ogawa F; Sato S; Takehara K
J Rheumatol; 2007 May; 34(5):1012-8. PubMed ID: 17309126
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
14. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review.
Kilinc OC; Ugurlu S
Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
[TBL] [Abstract][Full Text] [Related]
19. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
Oldroyd A; Sergeant JC; New P; McHugh NJ; Betteridge Z; Lamb JA; Ollier WE; Cooper RG; Chinoy H;
Rheumatology (Oxford); 2019 Apr; 58(4):650-655. PubMed ID: 30535395
[TBL] [Abstract][Full Text] [Related]
20. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.
Xing X; Li A; Li C
Respir Med; 2020 Oct; 172():106134. PubMed ID: 32905890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
